Mayo Clinic

Latest from Mayo Clinic


The Aducanumab Saga and the Future of Antiamyloid Monoclonal Antibodies

June 13, 2022

The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.

Aberrant Sleep Patterns Show Risk Associated With Status Migrainosus Recurrence

June 11, 2022

Data from a study in Olmsted County, Minnesota, identified the incidence rate of status migrainosus to be 26.60 per 100,000, with more than 10% of the cohort reporting that too much or too little sleep triggered the condition.

The Incidence of and Difficulties in Defining Status Migrainosus: Rashmi Halker Singh, MD, FAHS, FAAN

June 10, 2022

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]